Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression
Bruria Hirsh Raccah, A Yanovsky, Nir Treves, Victoria Rotshild, Christel Renoux, Haim Danenberg, Ran Eliaz, Ilan Matok
Topics & Concepts
MedicineProprotein convertaseKexinSubtilisinPCSK9Meta-analysisAdverse effectMeta-regressionInternal medicineOncologyPharmacologyCholesterolLDL receptorEnzymeLipoproteinBiochemistryChemistryLipoproteins and Cardiovascular HealthComputational Drug Discovery MethodsMicrobial Metabolism and Applications